Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485464 | 0.93 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL17968904 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL17825430 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL19807141 | 0.81 | ITGB3 (0.52) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL17825370 | 0.81 | ITGB3 (0.61) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL17834529 | 0.81 | ITGB3 (0.61) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL17968782 | 0.80 | ITGB3 (0.49) | ITGB3ITGA2BITGAVCTSLCTSS | |
| SCHEMBL17825315 | 0.80 | ITGB3 (0.49) | ITGB3ITGA2BITGAVCTSLCTSS | |
| SCHEMBL16295823 | 0.79 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGA4ITGB7 | |
| SCHEMBL16295824 | 0.79 | ITGB3 (0.49) | ITGB3ITGA2BITGAVITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB3 4025/4885ITGA2B 4142/4885ITGAV 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.